Persephone Biosciences, a pioneering biotech company focused on unlocking the potential of the microbiome to impact human health, today announced the launch of its first consumer product: a daily synergistic synbiotic for infants and toddlers. […]
Following the closure of Bacthera’s CDMO activities, Lallemand has acquired a broad range of state-of-the-art equipment to produce drug substances and drug products in anaerobic conditions, reinforcing its GMP Pharma production capabilities for next-generation strains. […]
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. The round was led by […]
Corn is one of the most valuable cash crops globally, with annual grain production in the United States alone valued at nearly $80 billion. Fungicides are widely used to protect crops and promote yield, but […]
In the past 10 years, there has been significant interest in new classes of active pharmaceutical ingredients (APIs). These novel APIs include live biotherapeutics, which are used for microbiome targeting drugs, oral biologics like GLP1 […]
COPENHAGEN, Denmark, Aug. 07, 2025 (GLOBE NEWSWIRE) — SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with funding from […]
Postbiotics are a quickly-growing category of products targeting gut health and other applications, such as skin. Defined in 2021 as “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the […]
The internationally recognized One Health Microbiome Center (OHMC) in the Huck Institutes of the Life Sciences at Penn State is the recipient of a new National Institutes of Health (NIH) grant to train doctoral students in biotechnological […]
As interest in biotics1 and their wide range of health applications continues to grow, BioGaia is proud to announce the launch of a subsidiary company, BioGaia New Sciences AB, dedicated to exploring opportunities in microbiome […]
A groundbreaking UK research network has been launched to uncover how the microbiota, gut, immune system and brain are inter-connected and how they can influence mental wellbeing. Work from the research network could potentially lead […]
Researchers have been working toward using the gut microbiome as a clinical target for screening for colorectal cancer. This would ideally allow simple stool tests to be used for early detection of the disease in […]